Mike Tyson Unveils New Cannabis Brand in New York

Business by 2FIRSTS.ai
Jan.22.2024
Mike Tyson Unveils New Cannabis Brand in New York
Hundreds of Mike Tyson fans lined up outside a New York pharmacy to support his new marijuana business venture.

According to a recent report by The New York Times, hundreds of followers of Mike Tyson, one of the greatest boxers of all time, lined up at a pharmacy in New York over the weekend in hopes of getting a chance to meet him and show support for his latest business venture: selling marijuana in his home state.

 

According to reports, 57-year-old Tyson has recently launched the Tyson 2.0 brand, emerging as one of the most notable newcomers in the New York cannabis industry. As the legalization of cannabis gradually spreads across the United States, actors, athletes, and musicians have been profiting from the marijuana industry through product lines and sponsorship contracts for over a decade. However, the trend has only recently started to gain momentum in New York. Tyson is seeking to test his fame and become a prominent figure in what is projected to become the world's largest and most competitive market.

 

The evaluations of cannabis brands backed by celebrities are mixed. While their sales often surpass those of traditional brands, they cannot compete with the biggest brand that sells millions of dollars worth of cannabis every month.

 

According to data from Headset, a specialized cannabis data company, out of the top 30 bestselling brands in California, the largest market in the United States, only 9 of them are owned or endorsed by celebrities. These include Tyson 2.0, actor Seth Rogen's Houseplant, and musician Carlos Santana's Mirayo.

 

One of the company analysts, Mitchell Laferla, noted that the ultimate driving factor for consumers in emerging markets like New York is value, and this is precisely where celebrity-endorsed brands face difficulties.

 

Consumers who spend lavishly are now seeking the most powerful features at the lowest prices, while the quality of celebrity brands varies, often commanding higher prices. In California, a bag of 3.5 grams typically sells for around $23.14, whereas Tyson 2.0 is priced at approximately $28.44, representing a 23% difference.

 

Lafra states that the success of Tyson 2.0 can be attributed to the way Tyson interacts with its clients and their companies, its proactive expansion into new markets such as New York and Maryland, and the quality of its products.

 

"Your name may entice someone to give it a try," he said. "But it's your brand and product quality that are the factors that keep people coming back."

 

Yuvraj Singh, the CEO of Long Island Strain Stars, has stated that customers have returned to purchase more cannabis from Tyson Foods. On the first day of the launch of their Tyson 2.0 flower line, their customers bought a total of $30,000 worth of cannabis products, making the cannabis series one of the top five best-selling products in the store.

 

According to reports, he described its effect as a highly pleasurable and refreshing sensation.

 

Coss Marte, co-owner and CEO of Conbud, has stated that their pharmacy has also attracted more customers to make purchases, selling $10,000 worth of Tyson 2.0 within an hour, which is equivalent to the pharmacy's typical daily sales.

 

Former boxing champion Mike Tyson has emphasized the therapeutic effects of marijuana in his transformation from an arrogant athlete to a disciplined businessman. In an interview, he revealed that less than a decade ago, he was penniless and struggling with a cocaine addiction. Today, he is the owner of one of the most successful celebrity marijuana brands in the country.

 

Tyson stated that his goal is to solidify his legacy as a pioneer of cannabis. "This is more important to me than making money," he declared.

 

Tyson was born into a financially disadvantaged family in Brooklyn and later discovered his boxing talent at a reform school in the north. He quickly became a teenage sensation and eventually won 50 professional matches, most of which were victories by knockout.

 

However, his reputation has been tarnished due to his antics, such as biting Hollyfield's ear, as well as his legal troubles, including a three-year prison sentence for a rape case that he still denies. In 2014, he revealed his dependency on cocaine and claimed that marijuana helped him break free from addiction. He currently resides in Las Vegas and owns a marijuana farm in California.

 

His personal story has attracted many fans, who seem eager to support him. "He has gone through some difficult times, and I can relate to that," said 26-year-old Tony Pedroza, a boxing enthusiast from Brooklyn who was standing in line in Manhattan to see Tyson.

 

Monifa Jones-Tuck and her husband, Troy Tuck, drove from Bethlehem, Pennsylvania to show their support for him. Jones expressed that they have been following Tyson's boxing career since the beginning and admire his progress.

 

"After using marijuana, his mind is currently in a good and calm state," he said. "It suits him well, and he also looks great."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
Juul Displays FDA-Authorized JUUL2, Highlights Age Verification at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Juul Labs displayed its JUUL2 e-cigarette system alongside existing products, age-verification messaging and mobile coupons, 2Firsts observed. The JUUL2 device and Virginia Tobacco and Polar Menthol pods received FDA marketing authorization in August 2026. Booth materials highlighted longer battery life, greater e-liquid capacity and connected-device features. A TruAge sign and a mobile coupon presentation also featured at the booth, with weekly offers available to age-verified adult nicotine consumers at participating retailers.
EXPO
Oct.09